Enteropathic spondyloarthritis by Mrsić, Fanika
  
 
UNIVERSITY OF ZAGREB 
SCHOOL OF MEDICINE 
Fanika Mrsić 
Enteropathic Spondyloarthritis  
GRADUATE THESIS 
 
 
 
 
 
Zagreb, 2016. 
  
 
UNIVERSITY OF ZAGREB 
SCHOOL OF MEDICINE 
Fanika Mrsić 
Enteropathic Spondyloarthritis  
GRADUATE THESIS 
 
 
 
 
 
Zagreb, 2016. 
  
 
This graduation paper was made at the Division of Clinical Immunology and Rheumatology; 
Department of Internal Medicine, Clinical Hospital Center Zagreb, School of Medicine, 
University of Zagreb under supervision of prof.dr.sc.Branimir Anić and it was submitted for 
evaluation in the academic year 2015/2016. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
ABBREVIATIONS  
APC   antigen presenting cells 
AS   ankylosing spondylitis 
axSpA   axial spondyloarthritis 
CD   Crohn’s disease 
CRP   C-reactive protein 
DMARD  disease-modifying antirheumatic drugs 
EA   enteropathic spondyloarthritis 
EIM   extraintestinal manifestations 
ESR   erythrocyte sedimentation rate 
HLA   human leukocyte antigen 
IBD   inflammatory bowel diseases 
IFN γ   interferon gamma 
IL   interleukin 
MDP   muramyl dipeptide 
NOD2/CARD15 nucleotide-binding oligomerization domain-containing protein 2 / caspase 
recruitment domain-containing protein 15 
NSAID  nonsteroidal anti-inflammatory drugs 
RF   rheumatoid factor 
SpA   spondyloarthritis 
TNF   tumor necrosis factor 
UC   ulcerative colitis 
 
 
  
 
TABLE OF CONTENTS 
  
    SUMMARY  
1. INTRODUCTION              1  
    1.1. Spondyloarthritis             1  
2. INFLAMMATORY BOWEL DISEASES           4 
    2.1. Crohn’s disease             4 
       2.1.1 Epidemiology             5 
       2.1.2 Etiology and pathogenesis            6 
       2.1.3 Clinical picture             8 
       2.1.4 Differential diagnosis            9 
       2.1.5 Diagnosis          10 
       2.1.6 Treatment          11 
    2.2. Ulcerative colitis         12 
       2.2.1 Epidemiology         12 
       2.2.2 Pathophysiology         12 
       2.2.3 Pathology          13 
       2.2.4 Clinical picture         14 
       2.2.5 Classification         14 
       2.2.6 Differential diagnosis        15 
       2.2.7 Diagnosis          15 
       2.2.8 Treatment          16 
 
  
 
3. ENTEROPATHIC SPONDYLOARTHRITIS      17 
    3.1. History           17 
    3.2. Epidemiology          17 
    3.3. Etiology          18 
    3.4. Clinical picture         25 
    3.5. Differential diagnosis         28 
    3.6. Diagnosis          29 
    3.7. Treatment          30 
4. CONCLUSION          34 
5. ACKNOWLEDGEMENTS        35 
6. REFERENCES          36 
7. BIOGRAPHY          43 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
SUMMARY 
ENTEROPATHIC SPONDYLOARTHRITIS 
Fanika Mrsić  
 
The inflammatory bowel diseases are chronic idiopathic inflammatory diseases of the 
gastrointestinal tract that may be complicated by a variety of extraintestinal manifestations such 
as primary sclerosing cholangitis, erythema nodosum, pyoderma gangrenosum, acute anterior 
uveitis, and aortic insufficiency. However, rheumatological manifestations are the most common 
with spondyloarthritis being the most prevalent one. Enteropathic spondyloarthritis can present 
before, be synchronous with, or after the diagnosis of inflammatory bowel disease with two 
subsets of joint involvement: axial and peripheral. It is believed that genetic, immunological and 
environmental factors play a crucial role in the development of enteropathic spondyloarthritis.  
Although the association between extraintestinal manifestations of symptoms coupled with 
inflammatory bowel disease have been recognized from before, the exact pathogenic mechanism 
and link between articular and gut involvement is still largely unknown. 
Functional studies in this particular field are still needed to understand the complex immune 
mechanism for these interrelated conditions in the future. 
Early recognition of enteropathic spondyloarthritis in inflammatory bowel disease patients 
requires a multidisciplinary approach in order to guide therapy, reduce morbidity, prevent future 
disability and to improve the quality of life in the affected patients. 
 
KEY WORDS: inflammatory bowel disease, extraintestinal manifestation, enteropathic 
arthritis, multidisciplinary approach 
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1. INTRODUCTION 
Crohn’s disease (CD) and ulcerative colitis (UC) are chronic inflammatory bowel 
diseases (IBD) that can be associated with joint disease as an extraintestinal manifestation 
(EIM) (1). Enteropathic spondyloarthritis (EA) is the most common and underestimated 
EIM in patients with IBD. EA belongs to the group of spondyloarthritis. The exact 
etiopathogenic mechanism and link between articular and gut involvement is still 
unknown.  
 
1.1 SPONDYLOARTHRITIS 
Seronegative spondyloarthritides (SpA) are a heterogeneous group of chronic 
inflammatory rheumatologic diseases of unknown etiology. The predilection sites are the 
spine and joints. Most commonly, it is marked by the presence of spinal and peripheral 
joint oligoarthritis, inflammation of sacroiliac joints and tendon attachments. For many 
patients, seronegative SpA does not only present with rheumatologic manifestations. 
Symptoms may occur elsewhere in the body including the heart valves, aorta, skin and 
eyes. A negative finding of rheumatoid factor (RF) and familial aggregation are 
something that diseases in this group have in common. The family of SpA encompasses a 
group of disorders that includes: ankylosing spondylitis (AS); psoriatic arthritis (PsA); 
reactive arthritis (ReA), known as Reiter’s syndrome; enteropathic arthritis (associated 
with IBD, Whipple’s disease, and “bypass” arthritis); and undifferentiated 
spondyloarthritis (uSpA). 
The main representatives of this group of diseases are shown in Table 1 (2) and 
classification criteria for SpA diagnosis are shown in Table 2 (2). 
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Table 1. The entities of seronegative spondyloarthritis (Modified according to Anić B, 
Babić-Naglić Đ, 2008)                                                                                     
1. Ankylosing spondylitis 
2. Psoriatic arthritis 
3. Reactive arthritis (SARA and EARA, Reiter’s syndrome) 
4. Enteropathic arthritis (IBD, Whipple’s diseases, “bypass” arthritis) 
5. Undifferentiated spondyloarthritis 
SARA – sexually acquired reactive arthritis; EARA – enterically acquired reactive 
arthritis 
 
Table 2. Classification criteria for seronegative spondyloarthritis (Modified according to 
Anić B, Babić-Naglić Đ, 2008) 
1. Asymmetrical peripheral arthritis 
2. Negative RF finding 
3. Absence of subcutaneous rheumatoid nodules 
4. X-ray signs of sacroiliitis with or without ankylosis 
5. Clinical overlap of symptoms of some diseases in this group (≥ 2 at the same 
time) 
6. Family history 
7. The presence of HLA B27 antigen 
 
The prevalence of the SpA group as defined by the European Spondyloarthropathy Study 
Group (ESSG) criteria has been reported in the ranges of 0.3 – 1.4% in Europe and the 
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United States (3,4). The occurrence of SpA among close relatives indicates a genetic 
predisposition in the development of the disease (2). A number of genetic factors have 
been investigated involving human leukocyte antigen (HLA) locus. The most frequently 
documented is HLA B27. Although the connection between HLA B27 antigen and the 
development of SpA is still not well understood and not all patients have a positive result 
for this antigen, a high incidence of HLA B27 was noted in SpA patients. 
Given the heterogeneity of diseases and symptoms in this group, therapeutic strategies 
require a multidisciplinary approach. The therapeutic principle for subsets of SpA does 
not differ from other inflammatory arthropathies. Most often used are nonsteroidal 
antiinflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs) 
and glucocorticoids. The most commonly used DMARDs are methotrexate, sulfasalazine, 
leflunomide and chloroquine. In the last several years, biological drugs represent a class 
of new drugs that are used in the treatment of SpA because of their proven 
immunosuppressive / anti-inflammatory and immunomodulatory effects. The main 
representatives of this group of drugs are inhibitors of tumor necrosis factor (TNF-α) as a 
targeted biological response modifier.  
Given that SpA has been historically underdiagnosed and unrecognized, early diagnosis 
is still a major challenge for clinicians in their everyday work.  
 
 
 
 
 
 4 
 
2. INFLAMMATORY BOWEL DISEASES 
Inflammatory bowel diseases (IBD) are chronic idiopathic inflammatory diseases of the 
gastrointestinal tract that are comprised of heterogeneous disorders such as Crohn’s 
disease (CD) and ulcerative colitis (UC), and to a lesser extent, indeterminate colitis and 
microscopic colitis. They have an unpredictable course and their incidence is rising in 
recent years. IBD are one of the most common chronic inflammatory diseases and overall 
as many as 1.4 million people in the United States and 2.2 million people in Europe 
suffer from these diseases (5) with a peak of incidence between 15 and 30 years of age 
(6). Etiology is not yet well known but it is likely multifactorial and results from the 
interaction of genetic and environmental factors. IBD can be complicated by a variety of 
extraintestinal manifestations with symptoms manifesting elsewhere in the 
gastrointestinal system such as hepatic and oral in addition to cutaneous, ocular and 
musculoskeletal systems. 
 
2.1 CROHN’S DISEASE 
Crohn’s disease is a chronic inflammatory disease of the gastrointestinal tract of 
unknown etiology that can affect any part of the gastrointestinal tract. It most commonly 
affects the terminal ileum but has the potential to affect any part of the gastrointestinal 
tract from mouth to anus with its main feature of transmural inflammation. It is a lifelong 
disease with a variable clinical course characterized by frequent remissions, 
exacerbations and EIM. The genetic and environmental factors seem to play a role in the 
etiology of CD.  
 
 5 
 
2.1.1 EPIDEMIOLOGY 
The incidence of CD is 0,1-16/100 000 and has increased during the past few decades (7). 
The incidence in Croatia is up to 7/100 000 (8). It usually begins between the ages of 15 
and 30. Studies show that genetics plays a big role in the development of CD. It is more 
frequent in women, Caucasians and in some families. Close relatives have a 10-15 times 
higher risk for disease development and family history is positive in 6-20% of CD 
patients (8). A recent 12-year study in Texas showed that Hispanics had a lower 
incidence (0.62/100,000) than African-Americans (1.83/100,000) or Caucasians 
(4.5/100,000). In that same study it was shown that African-Americans are more likely to 
develop CD that UC (9). 
The only proven risk factor for the development of CD is smoking. Interestingly, it is a 
protective factor for UC. Various environmental factors and their role in the pathogenesis 
of CD have been investigated, but so far none of them has proven to be a definitive cause 
of CD. Some of the potential environmental factors are showed in Table 3 (8). 
 
Table 3. Potential environmental factors associated with IBD (Modified according to 
Vucelić B, Čuković-Čavka S, 2008) 
Smoking 
Oral contraceptives 
Early childhood factors (early cessation of breastfeeding, hygiene, infection) 
Infections (Mycobacterium paratuberculosis, measles, rubella) 
Appendectomy 
Food (refined sugars, margarine, yeast, chocolate, Coca-Cola) 
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2.1.2 ETIOLOGY AND PATHOGENESIS 
Despite many studies over the past few decades, the exact etiology is not yet clear. The 
inheritance is complex-polygenic with several genes and environmental factors involved. 
It is believed that the dysregulated immune response to luminal bacteria in a genetically 
susceptible host is responsible for the development of CD. This means that genetics have 
an important if not decisive role in CD pathogenesis, as studies have shown.  
The first susceptibility gene for CD that was identified was nucleotide-binding 
oligomerization domain-containing protein 2 also known as caspase recruitment domain-
containing protein 15 (NOD2/CARD15) located on chromosome 16 (10).  It is involved 
in recognizing bacterial muramyl dipeptide (MDP) and stimulating the immune system to 
respond properly. Mutation of NOD2 leads to the inappropriate recognition of bacterial 
intestinal flora and with inadequate immunological response results in an inflammatory 
state. The precise mechanism by which the NOD2 mutations lead to inflammation is not 
quite clear but this discovery and NOD2 association with CD was highly significant for 
supporting the hypothesis in which CD-affected patients have an abnormal response to 
intestinal bacteria. Other genes that have been identified as important in the development 
of the disease are DLG5, OCTN1 and 2, TLR4, IL23R, ATG16L1, DRB*0301 (8). Many 
studies are investigating CD-associated gene changes and those results are important to 
determine how those genetic variations are related to a person's chance of developing 
CD.  
Abnormal intestinal permeability is another part associated with CD development. After 
bacteria are presented to antigen-presenting cells (APC) with subsequent antigen 
expression, T cells are activated resulting in an inflammatory state. Therefore, the Th1 
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response is predominant in CD with interferon gamma (IFNγ), TNFα and IL-12 as the 
main inflammatory mediators (8). 
Observation of an increase in the incidence of IBD and its association with improvements 
in hygiene in the 20th century has led to the hygiene hypothesis. It claims that children 
raised in a more sanitary environment are more likely to develop CD in comparison to 
those exposed to enteric pathogens in their early childhood (11). Multiple factors such as 
Helicobater pylori exposure, helminths, antibiotic use, measles infection and vaccination, 
domestic hygiene and breastfeeding have been implicated in this theory (11). For now, 
the accuracy of the hygiene hypothesis is not confirmed and further studies in this area 
are needed to understand the potential mechanisms underlying the hygiene hypothesis 
and associations with IBD. 
As can be seen, despite many various studies, the exact pathogenesis of CD is not yet 
fully known. It seems that inheritance is not enough for disease development but many 
explored, but also unexplored environmental factors are involved in the pathogenesis of 
CD. There is a strong need for future studies and researches in this area in the hope of 
understanding the mechanism and etiology of this disease. 
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2.1.3 CLINICAL PICTURE 
The clinical picture is complex since CD can affect any part of the gastrointestinal tract, 
from mouth to anus. 75% of patients have the small intestine affected of which 90% have 
the terminal ileum affected (8). The rectum is usually spared. Changes in the gut include 
cryptal inflammation and abscesses, granulomas, fibrostenotic and inflammatory 
strictures.  
The inflammation is transmural, involving the entire thickness of the intestinal wall with 
classical “skip lesions”. Transmural inflammation leads to the formation of a fistula 
between the bowel walls (enteroenteral), as well as between the bowel and vagina or the 
bladder (rectovaginal or enterovesicular, respectively). Narrowing of the intestine due to 
transmural inflammation leads to the characteristic spasms in the abdomen and possibly 
to the formation of intra-abdominal abscesses. The most prominent symptoms of CD are 
diarrhea, abdominal pain, weight loss, fatigue and bloody stools. Except intestinal 
symptoms, CD can manifest outside the gastrointestinal tract. EIM are not uncommon in 
CD patients (8). Some of them that are correlated with the intensity of bowel 
inflammation are arthritis, erythema nodosum, pyoderma gangrenosum and episcleritis. 
Others, such as primary sclerosing cholangitis, SpA and uveitis are not associated with 
IBD activity (8). CD can be complicated by various conditions depending on which part 
of the intestine is affected. Some of CD associated complications are sideropenic anemia, 
leukocytosis, disseminated intravascular coagulopathy, pyelonephritis, hydronephrosis, 
urolithiasis, thromboembolism and hypokalemic nephropathy. If the terminal ileum is 
affected, the place where vitamin B12 is absorbed, megaloblastic anemia can develop. 
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Also, if the CD affects the jejunum, patients have the potential to develop malabsorption 
syndrome.  
To assess the disease and its inflammatory activity, clinicians can use many composite 
clinical indices available for everyday use. Some of them are the CDAI (Crohn’s disease 
activity index), pediatric CDAI, Oxford Index, Cape Town Index, Harvey-Bradshaw 
Index etc. However, the most commonly used is CDAI (8,12). 
 
2.1.4 DIFFERENTIAL DIAGNOSIS 
As CD is a complex disease with very varied symptomatology, the differential diagnosis 
of CD includes many similar conditions. It is important to bear in mind all the possible 
differential diagnoses in order to detect the disease in a timely fashion and began 
treatment as soon as possible.  
Diseases whose clinical picture can mimic the picture CD are infections (Salmonella spp., 
Shigella spp., Campylobacter spp., Escherichia coli, Clostridium difficile), intestinal 
ischemia and vasculitis, malignant diseases (lymphoma, leukemia, adenocarcinoma), 
medication-induced colitis, celiac disease, appendicitis, diverticulitis. Those are just some 
of the potential diseases that one should think of given that many diseases have a similar 
clinical picture and symptoms as CD.  
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2.1.5 DIAGNOSIS 
Since there is no pathognomonic diagnostic test that could help us confirm the diagnosis 
of CD, the diagnosis of Crohn's disease can sometimes be challenging as it is based on 
the clinical presentation and on certain diagnostic tests.  
A complete blood count is used to evaluate the inflammatory disease activity. 
Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and fibrinogen are 
increased. In an active disease state, increased liver enzymes, hypoalbuminemia, 
leukocytosis, thrombocytosis and anemia can be found.   
To exclude specific pathogens and inflammation of the gastrointestinal tract as a possible 
cause of disease, a stool analysis can be done.  
The gold standard for the diagnosis of IBD is a gross inspection of the gastrointestinal 
tract that includes colonoscopy, esophagogastroduodenoscopy and in some cases capsule 
endoscopy. It is important to note that colonoscopy is contraindicated in the acute phase 
of the disease, in toxic megacolon, and when extensive fistulas are present. In addition to 
endoscopy, histopathological analysis of biopsy material is of great importance. 
Radiological imaging methods that are useful for locating affected regions of inflamed 
bowel and intraabdominal complications are an abdominal ultrasound (US) and computed 
tomography (CT). In order to evaluate and detect complex perianal disease, magnetic 
resonance imaging (MRI) is the method of choice (8). X-ray of the abdomen is of great 
importance in excluding toxic megacolon, ileus and perforation. Barium enema, on the 
other hand, is useful in detecting complications and evaluation of the entire colon when 
strictures of the colon do not permit the colonoscope to pass through. 
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A small bowel follow-through is useful when the disease involves only the small intestine 
because colonoscopy and gastroscopy cannot be used to evaluate the entire small 
intestine. 
 
2.1.6 TREATMENT 
The treatment of CD is determined by the activity, severity, location, and type of 
inflammation taking into account the previous response, complications and presence of 
EIM. Some of the drugs used are the aminosalicylates which are represented by 
mesalazine in the form of azo conjugates, delayed-release formulations or enema. For 
active disease or relapse, systemic glucocorticoids such as prednisone, prednisolone, 
methylprednisolone or hydrocortisone can be used but not for the maintenance of 
remission. Prolonged use of glucocorticoids has significant side-effects. As a result, they 
are, in general, not used for long-term treatment. Immunomodulatory drugs (azathioprine, 
6-mercaptopurine, methotrexate) are another option in the treatment of CD. Mostly, they 
are used in glucocorticoid resistant or dependent patients or when extensive disease is 
present (8). Additionally, they are effective in the maintenance of stable remission. For 
the treatment of sepsis and perianal disease, antibiotics can be applied, metronidazole and 
ciprofloxacin are the most common used ones.  
In the last few years, advancing knowledge regarding the biology of chronic 
inflammation has led to the development of drugs with targeted action towards certain 
molecules involved in the inflammatory response. This so called biological therapy is 
used to treat active, refractory CD and CD associated EIM. Some of TNF-α inhibitors 
used in the treatment of IBD are infliximab, adalimumab, golimumab, certolizumab 
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pegol. A new drug, vedolizumab, is showing some promising results in the treatment of 
patients who showed no improvement on anti-TNF therapy (13).  
However, more studies and data are needed for vedolizumab to be included as a treatment 
option for IBD.  Biological therapy has an important role in the treatment of IBD patients 
but still there are some concerns regarding its safety profile, especially when they are 
applied as long-term maintenance therapy (14). 
 
2.2 ULCERATIVE COLITIS 
UC is a lifelong idiopathic chronic inflammatory disease of the gastrointestinal tract that 
belongs to the group of IBD. It is an intermittent disease characterized by frequent 
remissions and relapses with continuous mucosal inflammation of colon, affecting the 
rectum and spreading proximally in a continuous and concentric manner. 
 
2.2.1 EPIDEMIOLOGY 
A higher incidence is observed in developed countries with 0.6-24.5/100 000 and in the 
past few decades it has been stable (8). It is more common in men and begins most often 
between the ages of 20 and 40 with a second small peak in incidence in people after the 
fifth decade of life. An appendectomy prior to the age of 20 and smoking, in contrast to 
CD, are protective factors against development of UC.  
 
2.2.2 PATHOPHYSIOLOGY 
The exact etiology is unknown. As in CD, the interaction of genetic and environmental 
factors play a role in its pathogenesis. The predominant type of response in UC is Th2 
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with production of IL-4, IL-5, IL-6, IL-10 and IL-13 (8). A number of antibodies have 
been described in patients with UC, of which the atypical perinuclear antineutrophil 
cytoplasmatic antibodies (pANCAs) are the best known. Positive pANCA serology is 
found in approximately 50–60% of patients (15). However, the sensitivity of pANCA is 
not so high to be used as a diagnostic tool. It can only help us to differentiate UC from 
CD. 
Certain genes have been associated with UC and some of them are HLA region, IL23R, 
DLG5, MDR-1, TLR genes and JAK/STAT pathway. All those results suggest that UC is 
a complex multifactorial and polygenic disease that leads to aberrant immunological 
response in genetically susceptible people.  
 
2.2.3 PATHOLOGY 
UC is characterized by an inflammation that is limited to the mucosa and submucosa. It 
begins in the rectum and extends proximally in a continuous pattern along the colon. The 
inflamed mucosa is red, granulated with spontaneous bleeding and ulcerations around 
which are islands of preserved mucosa. Not so uncommon are pseudopolips due to 
previous inflammatory conditions. The pathology in UC typically involves the distortion 
of crypt architecture, inflammation of crypts, crypt abscesses and mucin depletion. At a 
later stage of the disease due to recurrent attacks, various complications such as 
shortening of the intestines and toxic megacolon can occur.  
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2.2.4 CLINICAL PICTURE 
Since UC is restricted to the colon, the symptoms depend on the extent of the disease and 
inflammation. The primary presenting symptom of ulcerative colitis is bloody stools, 
reported by more than 90% of patients (15). Usually, the stool is mixed with mucus and 
pus. Patients also report diarrhea, tenesmus, urgency, occasionally severe constipation 
and crampy abdominal pain, or ache over the left iliac fossa prior to and relieved by 
defecation. UC is associated with a general inflammatory process that affects many parts 
of the body. EIM, especially an axial or peripheral arthropathy, episcleritis, erythema 
nodosum and pyoderma gangrenosum may be present in 10% of UC patients (16).  
 
2.2.5 CLASSIFICATION 
It is recommended for UC to be classified according to disease extent since the extent of 
UC will influence the treatment modality and determine if oral and/or topical therapy will 
be applied. For instance, topical therapy in the form of suppositories or enemas is often 
the first line choice for distal disease, but oral therapy is appropriate for extensive colitis.  
For the assessment of disease activity we use several clinical indices of which the most 
commonly used one in daily practice is Truelove and Witt’s criteria (8). This index 
defines UC as mild, moderate or severe based on some clinical factors such as 
temperature, pulse, CRP, ESR, bloody stools and hemoglobin. Truelove and Witts’ 
severity index is shown in Table 4 (17).  
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Table 4. Disease activity in ulcerative colitis (Adapted from Truelove and Witts) 
 Mild Moderate Severe 
Bloody stools/day <4 ≥4 ≥6                and 
ESR <20 mm/h ≤30 mm/h >30 mm/h      or 
CRP Normal ≤30 mg/L >30 mg/L      or 
Hemoglobin >11.5 g/dL ≥10.5 g/dL <10.5 g/dL     or 
Pulse <90 bpm ≤90 bpm >90 bpm        or 
Temperature <37.5 °C ≤37.8 °C >37.8 °C 
  
 
2.2.6 DIFFERENTIAL DIAGNOSIS 
Many diseases have similar symptoms to UC and can present in a similar manner. The 
differential diagnosis described for CD is the same as for UC.  
 
2.2.7 DIAGNOSIS 
Given that the gold standard for the diagnosis of UC is not available, the diagnosis should 
be based on a combination of medical history, clinical evaluation, endoscopic and 
histological findings.  
The diagnostic workup we use in the diagnosis of UC is similar if not the same as in CD. 
This includes: laboratory analysis, endoscopy, radiological and histopathological 
analysis. The best test for the diagnosis of ulcerative colitis is still endoscopy, most 
commonly rectoscopy. To assess the extent of the disease usually colonoscopy, capsule 
endoscopy and esophagogastroduodenoscopy are used.  
 16 
 
2.2.8 TREATMENT 
The treatment of UC may be mainly pharmacological or surgical. The goal is to induce 
remission followed by maintenance and to prevent a relapse of the disease. Treatment 
depends on the disease activity and severity. For distal disease (proctitis, 
proctosigmoiditis) topical therapy is applied. First –line treatment is topical mesalazine 
with or without oral mesalazine. For those patients who are nontolerant to 
aminosalicylates, glucocorticoids as second-line therapy can be prescribed. Treatment of 
extensive disease requires oral aminosalicylates/glucocorticoids or i.v. hydrocortisone/ 
methylprednisolone in the case of left-sided colitis and severe colitis, respectively. 
Mesalazine, aminosalicylates and 6-mercaptopurine are used for the maintenance of 
remission.  
Unlike in CD, UC can generally be cured by surgery. The procedure is proctocolectomy 
with ileoanal anastomosis. It is necessary in the event of extensive hemorrhage, frank 
perforation, toxic megacolon, resistant fulminant colitis nonresponsive to therapy, colon 
cancer or in severe hemolytic anemia.  
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3. ENTEROPATHIC SPONDYLOARTHRITIS 
Enteropathic spondyloarthritis or enteroarthritis (EA) is a nonerosive oligoarticular 
episodic migrating peripheral arthritis that belongs to a group of seronegative 
spondyloarthritides which occur in patients with IBD and other gastrointestinal disorders 
such as Whipple’s disease and after intestinal bypass surgery.  
 
3.1 HISTORY 
A relationship between joints and bowel was first reported by Smith in 1922. He 
described an improvement of articular symptoms in rheumatoid arthritis (RA) patients 
who underwent colectomy (18). Later on, in 1929 and in 1935 Bargen et al. and Hench 
respectively, reported the arthritis tendency to flare upon exacerbation of colitis and to 
recede with remission of the intestinal symptoms (19). Although the occurrence of 
sacroiliitis in IBD patients was described by some authors in the 1950s, it was not until 
1964, that the American Rheumatism Association recognized and classified arthritis 
associated with IBD as an independent clinical form (20) and this marked the turning 
point in the earlier understanding of that disease. A further study of joint and bowel 
relationship was postulated by Wright and Moll who included EA in the SpA group (21).  
 
3.2 EPIDEMIOLOGY 
Establishing the true prevalence of EA is challenging due to the use of different 
diagnostic criteria, methodological approaches, the difference in study design and 
sampling methods, the frequency of IBD in different geographic areas and the variability 
in the prevalence of HLA-B27 among different racial groups. 
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The prevalence of EA according to the Italian population is 0.09% and 0.02% according 
to a Swedish study (22). EA occurs most frequently between the ages of 25 and 50 and 
equally in both sexes, however, somewhat more often in men (8).  
Rheumatologic findings are more frequent in patients with disease confined to the colon 
(23).   60-70% of patients with SpA have gut inflammation. Spinal or articular 
manifestations occur in 5%-20% of IBD patients. Arthritis and sacroiliitis are found in 
10-20% patients and spondylitis in 10% of patients with IBD. Women tend to have more 
frequent peripheral joint involvement while men tend to have more axial joint 
involvement (24,25).  
Sacroiliitis and spondylitis are associated with HLA B27 (40% and 60% respectively) but 
to a lesser degree than in uncomplicated AS (90%). Peripheral arthritis showed no 
connection with HLA B27. Potential risk factors for EA development are active bowel 
disease, family history of IBD, appendectomy, smoking and the presence of other EIM 
(26,27).  
 
3.3 ETIOLOGY 
The exact etiology of EA is still not fully understood despite many studies being 
conducted over the past decade.  
It is believed that the combination and interaction of genetic, immune factors and 
bacterial gut infections play an important role in the emergence and development of the 
disease with environmental factors having a causative role in triggering the onset of the 
disease. Current theories suggest that aberrant migration of intestinal lymphocytes and 
macrophages from inflamed gut mucosa to joints in genetically susceptible people leads 
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to an abnormal state and immunological intolerance due to dysfunctional interaction of 
the immune system and gut bacteria (19,28).  
IBD and SpA show familial clustering and may coexist in a patient. Various 
epidemiological studies have described the role of the HLA system in the development of 
EA. Among the genetic factors, the most studied one is HLA- B27 and it has shown the 
strongest genetic association with SpA being present in >90% of patients with AS in 
contrast to only 5-15% prevalence in the general population (29). It has more than 30 
subtypes that differ by only single amino acids. Only a few of those subtypes are 
associated with AS (e.g. HLA-B*2705, HLA-B*2702, HLA-B*2704 and HLA-B*2707) 
(30). The 4 main theories that describe its role in the pathogenesis of AS are shown in 
Table 5 (30). 
 
Table 5. Theories on the pathogenesis of SpA related HLA- B27 (Modified according to 
Voulgari PV,2011 ) 
1. The arthritogenic peptide hypothesis 
2. Alteration of intracellular handling of microbes 
3. Recognition of HLA-B27 as an autoantigen 
4. Self-association of the HLA-B27 molecule 
 
One theory suggests that HLA-B27-expressing macrophages bind a set of antigenic 
peptides. They then expose the bacterial antigens and activate the T-cell response with 
migration of T –cells from the gut to the joint leading to the development of arthritis (31).  
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The second theory proposes that HLA-B27 leads to a less effective elimination of 
microbes with upregulation of pro-inflammatory cytokines. 
Another, the third theory, also known as the molecular mimicry hypothesis, represents 
the sequence homology between HLA-B27 and bacterial antigens where HLA-B27 is 
presented by HLA class II heterodimers and recognized by CD4+ T- cells as an 
autoantigen. Because of this peptide homology, activation of T-cells by the mimicry 
mechanism leads to an inflammatory state. 
The most recent theory, the self-association of HLA-B27 molecule, is based on 
endoplasmic reticulum stress. The production of inflammatory cytokines is induced by 
misfolding of the heavy chains of HLA-B27 within the endoplasmic reticulum because 
the folding process of HLA-B27 heavy chains is slower than that of other HLA alleles. 
Accumulation of misfolded proteins results in chronic inflammation due to activation of 
the endoplasmic reticulum-unfolded-protein-response and nuclear factor κB (NFκB). 
Also, those B27 homodimers can be expressed on the cell surface and act as antigens 
producing an auto-inflammatory response without the need for antigen or by migration to 
cell surface HLA-B27 present peptides to other inflammatory cells.  
To conclude, the association of HLA-B27 with SpA-associated IBD is still higher than in 
the IBD population without SpA, and therefore, HLA-B27 in IBD patients seems to 
increase the risk of EA development (32). 
In addition to HLA-B27, other genes have been documented as being related to SpA and 
IBD. The genome scans have identified potential susceptibility genes that might have a 
role in the pathogenesis of SpA and IBD. The most prominent association documented 
was with IL-23 receptor polymorphism (33). It was shown that IL-23 is the only 
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susceptible gene shared by SpA and IBD so far. Its functional role is still not clearly 
defined but it is associated with an increased risk of developing AS and IBD. Binding of 
IL-23 to its receptor activates various signaling molecules and the production of 
cytokines (34).  
Loss of homeostasis between regulatory T-cells (Treg) and proinflammatory Th17 cells 
can also lead to an aberrant immune response. Reduced ratio of Treg to Th17 cells creates 
a proinflammatory environment, supporting the expansion and expression of Th17 cells 
(35). Interestingly, a connection between IL-23 and Th17 was established. Although the 
role of IL-23 is still unclear, it is believed that IL-23 signaling has a role in inflammation, 
mediated by Th17, by promoting expression and production of IL-17, IL-22 and TNF-α, 
indicating that Th17 could represent a common pathogenic mechanism in the 
development of both SpA and IBD (19, 34). This new pathway: IL-23/IL-17 axis is a 
potential treatment target for EA and can be a valuable addition to the currently available 
treatment of IBD-associated spondyloarthritis.  
NOD2/CARD15, also called inflammatory bowel disease protein 1, is another protein 
that plays an important role in the immune system and the development of CD. Its main 
function is to detect bacterial antigen and stimulate an appropriate immune reaction 
against it. The mutation of CARD15 results in inappropriate bacterial elimination and 
disrupts the protein’s ability to recognize and respond to microbial challenges. CARD15 
is seen in increased concentrations in AS patients with developed IBD (36,37) but studies 
have not shown its association with primary AS. Therefore, mutation of CARD15 is for 
now, considered a risk factor for bowel inflammation in SpA patients although its role in 
the process of intestinal bacteria presentation remains unclear. 
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To summarize, IL23 receptor is the only identified susceptibility gene and first common 
risk gene for primary AS, UC and CD, unlike CARD15, a risk factor for CD in SpA, 
which does not appear to define the overall disease susceptibility (38). As we can see, 
many studies have investigated the role of various genes in the pathogenesis of SpA and 
IBD in order to try to explain the interaction of those two complex diseases. Still, not 
enough is known and further studies are needed to detect the genetic component shared 
by these interconnected diseases.  
Altered barrier function of the gastrointestinal tract and the subsequent increase in 
intestinal permeability, allowing gut bacteria or antigens to interact with the immune 
system, results in entry of gut bacteria into the subepithelial layer and inflammation of 
the gut (39). Altered permeability has been demonstrated in patients with both SpA and 
their healthy first- degree relatives. Some studies showed an increase in small intestine 
permeability in rheumatoid arthritis, SpA and IBD patients although other studies have 
failed to reach the same result (40,41). Because of this, the role of gut inflammation in 
the pathogenesis of Spa and IBD has yet to be proven.  
The proposed mechanism and the role of the gut permeability in pathogenesis of SpA and 
IBD is as follows: disturbance of the barrier function in the gastrointestinal system leads 
to gut microbiota changes and gut inflammation. In such chronic inflammatory 
conditions, APC cells present antigens to naïve T-cells which continuously circulate 
between lymphoid tissue and blood. Upon encounter with the antigens, T-cells 
proliferate, differentiate and reach the site of inflammation by means of CCR9 and 
CCL25 (39). Under the influence of cytokines, other endothelial cells express VAP-1, 
VCAM-1 and ICAM which then bind to the activated T-cells. Salmi et al. (42) discovered 
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that VAP-1 is expressed preferentially in inflamed synovial tissue and supports binding 
of all leukocytes. Additional adhesion molecules such as VCAM-1 and ICAM that are 
present in the small intestine also adhere to synovial vessels. Once the mucosa is 
breached, T-cell tolerance to normal gut microbiota is damaged. Activated T-cells from 
the intestinal mucosa through the systemic circulation enter the joints and generate a 
specific immune response against the synovium causing an inflammatory state there as 
well. It was shown that lymphocytes from the gut of IBD patients are ten times more 
capable of binding to the synovium as compared to healthy controls. Given that, altered 
trafficking of gut lymphocytes might be another contributable factor in the 
immunopathogenesis of EA as a connection between IBD and SpA development.  
Microbiota of the gut refers to the ecological community of commensal, symbiotic and 
pathogenic microorganisms within an individual. The human gastrointestinal system 
harbors extremely complex microbiota with more than thousands of different bacterial 
species that increase in number from the stomach to the colon reaching its maximum 
numbers in the colon i.e.1011-1012 CFU/ml of luminal content. Dominant bacteria in the 
small intestine are the facultative anaerobes, whereas in the large intestines it is the 
obligate bacteria (39). This community of living microorganisms is stable throughout life 
and continuous host-bacterial interaction aids in food digestion and absorption and in the 
production of metabolites. Commensals provide a protective role to the host by 
preventing adherence of pathogenic bacteria to the mucosal layer, regulation of epithelial 
proliferation and maintenance of immune homeostasis. Because of this huge antigenic 
load present in the gastrointestinal tract, the immune system has to continuously 
communicate with the gut bacteria to prevent an aberrant state of inflammation by 
 24 
 
constantly downregulating mucosal immune cells (43). This process is known as “oral 
tolerance”. Previous studies suggested that enteric commensals can be an environmental 
trigger of AS in genetically susceptible people and that loss of immune tolerance can lead 
to chronic inflammation (44). With further investigations, several species have been 
recognized as potential causes in the pathogenesis of SpA and IBD. Some of them are: 
Bacteroides vulgatus, Klebsiella pneumoniae, Disulfovibrio disulfuricans, Salmonella 
spp., Campylobacter spp. and Yersinia enterocolitica. As previously mentioned, bacteria 
from the circulation can lodge in the joints with the uptake being more pronounced when 
arthritis is present. The presence of bacterial components within synovial joints was an 
interesting finding since the joint was assumed to be a sterile environment (45).  
Bacterial antigens have been isolated in joints of affected people indicating that bacteria 
and their antigens can play an important role in initiating arthritis when gut inflammation 
is present. Confirming this theory, HLA-B27 transgenic animal models have also shown 
the role of normal gut flora in the pathogenesis of SpA. These rats have spontaneously 
developed a colitis and axial and peripheral arthritis. Surprisingly, when kept in a germ-
free environment, these rats were protected from gut and joint inflammation. 
Furthermore, on exposure to gut bacteria, especially Bacteroides spp. colitis and arthritis 
developed in 83% by 3 months (44). Thus, it appears that bacteria are important factor in 
the pathogenesis of both SpA and IBD due to their interaction with the host’s immune 
system.  
To conclude, the exact pathogenetic autoimmune mechanism of EA is still not defined. 
SpA and IBD share many genetic and pathogenic features. Many studies have been 
conducted showing that in genetically susceptible individuals, altered gut permeability, 
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bacterial antigens and various potential genes are implicated in the development of those 
two complexes diseases. Although SpA and IBD share many risk genes and 
immunological evidence for shared pathogenesis have increased our understanding of 
these two interrelated disorders, further molecular and functional studies are needed for 
providing us with the evidence of a common pathogenetic mechanism.  
 
3.4 CLINICAL PICTURE 
Articular complications are the most common EIM in IBD. Arthropathies associated with 
IBD belong to the SpA group of disorders. Arthritis can affect the spine, sacroiliac joint, 
peripheral joints, or a combination of these sites. 
 Joint involvement is divided by the Assessment in Spondyloarthritis International 
Society (ASAS) classification in two subsets: axial (including sacroiliitis with or without 
spondylitis) and peripheral (46). Peripheral or axial articular involvement can precede, be 
synchronous with, or develop following the diagnosis of IBD, often by as many as 10 
years. 
Diagnosis of axSpA is based on clinical features of inflammatory low back pain 
supported by radiological changes of sacroiliitis with the MRI being the diagnostic tool 
of choice. HLA-B27 is over-expressed in axSpA but it has a lower prevalence than in 
idiopathic AS; 25-75% versus 7-15% respectively; making it of no diagnostic value (47).  
The prevalence of axial involvement in IBD patients is 5-12%. It is more prevalent in 
men with male to female ratio of 3:1. 
Axial involvement is more common in CD patients (5-22%) than in UC (2-6%) (48) and 
can precede the onset of enteritis by many years. University Health Network in Toronto 
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conducted a cohort study and results showed that 52% of IBD patients experienced bowel 
symptoms after the onset of SpA symptoms, 39% patients experienced symptoms prior to 
the onset of SpA and only 9% had bowel and SpA symptoms concurrently (49). 
Symptoms generally are not synchronous with bowel activity and are independent of 
exacerbation of bowel inflammation. The main complaints are pain in the pelvis after rest 
with morning stiffness which is then relieved by movement, exacerbated by coughing and 
sneezing, persistent lower back pain usually before the age of 45 years with duration of at 
least 3 months (30,50). The clinical course is similar as in idiopathic AS with squaring of 
the vertebral bodies, marginal syndesmophytes and cervical spine immobility - ankylosis 
with classical presentation of the so-called “bamboo spine” (51). 
Extra-axial manifestations of IBD-associated arthritis include peripheral arthritis, 
enthesitis, dactylitis, uveitis, and psoriasis. 
Peripheral arthritis is an inflammatory arthropathy, RF–negative, nondeforming, and 
nonerosive. It is the most frequent finding in IBD patients (17-20%) (52) and it is more 
prevalent in CD (53). Arthritis occurs equally in males and females between the ages of 
25 and 45 years and is generally more common in patients with colonic disease rather 
than those with small-bowel disease. In addition, arthritis is more common in CD with 
colonic involvement than UC and is more common in UC with pancolitis than isolated 
left-sided disease. (19,53) 
Diagnosis is based on signs of inflammation and exclusion of other forms of arthritis 
(47).  
Peripheral arthritis, occurring in 5–20% of IBD patients, classically involves large 
weight-bearing joints of the lower limbs (knees, ankles and metatarsophalangeal joints) 
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and presents as asymmetric monooligoarthritis. It is generally acute in onset with peak 
within 48 hours. The course is episodic, recurrent with spontaneous reduction within 6 
months (19). A small percentage will go on to become a chronic form (10-20%) (38). 
Exacerbations follow the extent and severity of IBD and stable reduction was seen after 
colectomy (54).  
The ASAS guidelines divided peripheral arthritis into oligo- or pauci-articular (type I) 
and poly-articular (type II) types. 
Type I is a pauciarticular arthritis affecting fewer than 5 large joints. Occurring in 
approximately 3.6% of UC patients and 6% of CD patients (53). It is usually asymmetric, 
acute, self-limiting and associated with active bowel disease. On clinical examination, 
tender painful swollen joints are observed.  It is generally migratory and transient without 
permanent joint damage. Type I is associated with HLA-DRB1*0103. This allele is found 
in 35% of type I patients in comparison to 3% of controls (55). 
Type II is a polyarthritis (involving ≥ 5 joint) mainly affecting the small joints of the 
hand as a symmetrical, seronegative arthropathy. It affects 3-4% of IBD patients (30). 
Symptoms can last for months or years independent of IBD activity. It may persist after 
colectomy and exacerbations can continue for years (30,51). Diagnosis is based on the 
clinical picture and exclusion of other forms of arthritis. Type II is associated with HLA-
B44* in 62% of patients in contrast to 30% of controls (55). Summary of type I and type 
II peripheral arthritis is shown in Table 6. 
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Table 6. Type I and Type II peripheral arthritis  
 Type I Type II 
Joint involvement <5 joints ≥5 joints 
Pattern Asymmetric Symmetric 
Acute/chronic Acute Chronic 
IBD activity - associated + - 
HLA region HLA- DRB1* HLA-B44* 
Exacerbations - + 
Limbs affected Lower limbs Upper limbs 
 
 
3.5 DIFFERENTIAL DIAGNOSIS 
The differential diagnosis of joint pain in patients with IBD is broad. Because EA is 
characterized by various clinical features that are not specific and pathognomonic for this 
entity, clinical signs must be differentiated from those of other SpA, rheumatoid arthritis 
and other connective tissue diseases. Due to overlap with some other rheumatological 
diseases, we also need to include secondary hypertrophic osteoarthropathy, 
glucocorticoid-associated osteonecrosis, and septic arthritis into our differential 
diagnosis. Similar symptoms and clinical picture of EA with ReA, sarcoidosis, 
“bypass”arthritis, Whipple’s disease, Adamantiades-Behçet’s disease and gluten sensitive 
enteropathy provide us with other differential diagnoses that must be taken into account 
when considering EA as the main disease. 
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3.6 DIAGNOSIS 
The diagnosis of EA is based on the clinical presentation and linkage of rheumatologic 
and bowel symptoms together with the exclusion of other specific forms of arthritis. 
There is no pathognomonic finding that could lead us to the diagnosis of arthritis due to 
IBD and it is important to recognize IBD and its associated EIM. Most laboratory 
findings are also nonspecific. Usually they follow IBD activity and they don’t have a 
major role in setting up a definitive diagnosis of EA. Anemia, as one of frequent findings 
in IBD patients reflects both iron deficiency anemia and anemia of chronic disease. 
Thrombocytosis and leukocytosis are also not uncommon findings in EA. Markers of 
inflammation such as ESR, CRP are increased but all those are nonspecific acute-phase 
reactants and are present in many other inflammatory states. RF and antinuclear 
antibodies as markers of inflammatory rheumatic diseases are negative. Analysis of 
synovial fluid and radiological findings are not characteristic. There are mild to marked 
inflammatory changes with white blood cells ranging from 1,500-50,000/mm3. Glucose 
levels are not reduced and microbiologic cultures are negative (56). Nonspecific 
abnormalities are also seen while performing synovial membrane biopsy. Usually 
proliferation of synovial lining cells, increased vascularity with mononuclear cell 
infiltration is seen (30). It is important to exclude septic arthritis by joint aspiration 
because the clinical presentation in IBD patients can be atypical due to anti-
inflammatory/immunosuppressive therapy that those patients are receiving.  
According to European Crohn’s and Colitis Organisation (ECCO), the diagnosis of 
axSpA is based on the clinical picture of inflammatory lower back pain associated with 
MRI or radiographic features of sacroiliitis. Radiologic evidence of sacroiliitis occurs in 
 30 
 
20-50% of patients with UC and CD, but progressive ankylosing spondylitis occurs in 
only 1-10% of patients (47). MRI can identify early sacroiliitis in symptomatic patients 
with normal plain radiology.  
The diagnosis of peripheral arthropathy and enthesitis associated with IBD is generally 
not accompanied by radiographic changes and is based on signs of inflammation and 
exclusion of other specific forms of arthritis (47). 
To conclude, when diagnosing EA, clinical examination, laboratory and radiologic tests    
must be taken into account to obtain the broad picture of its interaction, coherence and 
integrity. 
 
3.7 TREATMENT 
Therapy of EA patients should include a rheumatologist and a gastroenterologist with 
their active cooperation in order to reduce inflammation and prevent disability or 
deformity.  
When choosing a treatment, the therapeutic approach must be comprehensive and tailored 
to the requirements of the individual patient taking into account disease activity, clinical 
presentation and  general condition of the patient, age, sex, comorbidities, and treatment 
which he or she is taking. 
Non pharmacologic treatment includes rest and physical therapy. The goal of physical 
therapy is to maintain overall functional capacity of the patient, spinal mobility and to 
prevent deterioration and deformities of the spine that could lead to respiratory 
compromise and disability. Swimming, breathing exercises and medical gymnastics are 
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preferred as additional help to prevent possible unwanted consequences from developing 
(30).   
Pharmacological treatment is primarily directed at the treatment of the underlying bowel 
disease. The use of analgesics, NSAIDs, DMARDs, glucocorticoids and anti-TNFα drugs 
is usually enough to treat most of the symptoms.  
NSAIDs are prescribed to keep peripheral arthritis, back pain and stiffness under control. 
However, caution is necessary particularly in UC patients because of their potential effect 
on IBD exacerbation.  Cyclooxygenase-2 selective inhibitors could be prescribed for EA 
patients because of their effects on epithelial proliferation and wound healing but their 
effect is of very limited value and in clinical practice is not often prescribed as a therapy 
for EA patients. In a recent study it was shown that Cox-2 selective agents may be better 
tolerated in the short term but their side effects such as cardiovascular toxicity limit their 
usage and overall benefit in EA (30). Despite the concerns about side effects and 
potential worsening of IBD, rheumatologists and gastroenterologists have used NSAIDs 
and Cox-2 inhibitors to good effect successfully in IBD patients with limited risk of 
exacerbating the bowel symptoms. However, if a clinical picture worsening is noticed, 
discontinuation of these drugs is advised.  
Patients with axial SpA because of its potential disabling course, should be managed by a 
rheumatologist. Initial nonpharmacological approach is recommended in patients with 
axSpA. This includes physiotherapy and education. Usually, NSAIDs are used as a first-
line therapy for stiffness and pain but only in the short term when they are well tolerated. 
Long term NSAID therapy should not be used as a treatment of axSpA (47). Although 
some studies have shown that high dose of NSAID are associated with an increase of 
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disease activity, the use of etoricoxib and celecoxib (COX-2 inhibitors) may even be 
safer with a lower risk of disease flaring when compared to conventional NSAIDs. 
Methotrexate and sulfasalazine are of limited efficiency and value in the treatment of 
SpA symptoms and literature does not support the use of DMARDs and systemic 
glucocorticoids for axSpA.  
The induction of anti- TNFα agents as targeted biological response modifiers, had a 
major impact in the treatment of both IBD and axSpA. They should be used in order to 
reduce the progression of early nonradiologic axSpA in patients who are intolerant and 
refractory to NSAIDs or with some contraindications for NSAID use (57). The most 
widely used TNF-α inhibitors are infliximab and adalimumab. Both of these drugs are 
effective in IBD, axSpA and peripheral arthritis. Etanercept, another representative of the 
group, can control CD-associated arthritis but its effect on bowel disease itself is 
marginal. In the case of primary non-response or intolerance, switching to a second TNF-
α inhibitor was shown to be beneficial. A pegylated humanized antibody (certolizumab) 
is approved in Switzerland as a drug for the treatment and maintenance of response in 
patients with moderate to severe CD who had an inadequate response to previously 
mentioned therapy. It is has not yet been approved by the European Medicines Agency 
but preliminary results show that certolizumab could be beneficial in patients who in the  
first place responded to infliximab but have over the time lost the response or become 
intolerant to it (30,58). Precaution measures should be taken as for all patients on anti-
TNFα agents with skin test for tuberculosis and evaluation for latent infection prior to the 
initiation of the anti-TNFα therapy. 
 33 
 
In patients with peripheral arthritis, the treatment of underlying gut inflammation is 
usually sufficient. Symptomatic relief with short term glucocorticoids, NSAIDs and local 
steroid injections has a proven effect. Oral glucocorticoids are effective but only in the 
short term and should be discontinued as soon as possible. When disease duration is short 
or ESR is increased, sulfasalazine can be used as therapy for IBD associated arthritis. 
Although some studies have shown that sulfasalazine was not superior to placebo (59), it 
is still optimal treatment in SpA patients with peripheral disease and in large joint 
arthropathy. 
The main biologic agents used in IBD - associated arthritis are TNF-α inhibitors: 
infliximab, adalimumab, golimumab. They have been found to induce and maintain 
remission in persistent disease that affects the quality of life.   
New biologic therapies have been investigated due to our better understanding of the 
genetics and pathogenesis of CD, UC and EA. One such example is vedolizumab that is 
effective in moderate-to-severe IBD but its effect on IBD-associated arthritis has yet to 
be studied (60). Some promising results were shown with inhibition of IL-12/23 and IL-
17, ustekinumab and secukinumab, respectively. However, further studies are required to 
prove the effectiveness of new targeted therapies and their role in the future treatment of 
EA.  
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4. CONCLUSION 
EA is a nonerosive oligoarticular episodic migrating peripheral arthritis that belongs to a 
group of seronegative spondyloarthritides which occurs in patients with IBD. The exact 
etiopathogenesis and the link between articular and gut involvement is not yet known but 
it is believed that the interaction of genetic, immune factors and bacterial gut infections 
play an important role in the emergence and development of the disease with 
environmental factors having a causative role in triggering the onset of disease. Many 
studies have been conducted showing that altered gut permeability, bacterial antigens and 
various genes are implicated in the development of EA in genetically susceptible people. 
Joint involvement in EA is classified in two subsets: axial and peripheral that can 
precede, be synchronous with, or develop following the diagnosis of IBD. Diagnosis is 
based on the clinical presentation, linkage of rheumatologic and bowel symptoms with 
exclusion of other specific forms of arthritis. Non pharmacologic treatment includes rest 
and physical therapy. Pharmacological treatment is primarily directed at the treatment of 
the underlying bowel disease. The use of analgesics, NSAIDs, DMARDs, glucocorticoids 
and anti-TNFα drugs is usually enough to treat most of the symptoms. The recognition of 
EA requires a multidisciplinary approach and active cooperation between 
rheumatologists and gastroenterologists in order to reduce inflammation, prevent 
deformity and worsening of quality of life in IBD patients. 
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